



## **Oncothyreon Regains Compliance with NASDAQ Minimum Bid Listing Requirement**

**Bellevue, Washington — January 2, 2008** — Oncothyreon Inc. (NASDAQ: ONTY, TSX:ONY) today announced that it has received a letter from The Nasdaq Stock Market, indicating that the Company has regained compliance with the \$1.00 per share minimum closing bid price requirement for continued listing on the Nasdaq Global Market, pursuant to Nasdaq Marketplace Rule 4450(a)(5). In the letter, Nasdaq advised the Company that this matter is now closed.

### About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information visit [www.oncothyreon.com](http://www.oncothyreon.com).

### Investor and Media Relations Contact:

Julie Rathbun  
Rathbun Communications  
(206) 769-9219  
[ir@biomira.com](mailto:ir@biomira.com)

ONCOTHYREON INC., 110 - 110th Avenue NE, Bellevue, WA 98004  
Tel: (425) 450-0370  
Fax: (425) 450-0371

ONCOTHYREON CANADA INC. 2011 - 94 St. Edmonton, AB, Canada T6N 1H1  
Tel: (780) 450-3761  
Fax: (780) 463-0871  
<http://www.oncothyreon.com>